Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

Amy H. Tang, Richard A. Hoefer, Mary L. Guye, Harry D. Bear

Open source

DOI
10.20517/cdr.2022.31
Published
2022
Container
Cancer Drug Resistance
Publisher
OAE Publishing Inc.
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.20517/cdr.2022.31,
  title = {Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer},
  author = {Amy H. Tang and Richard A. Hoefer and Mary L. Guye and Harry D. Bear},
  year = {2022},
  journal = {Cancer Drug Resistance},
  doi = {10.20517/cdr.2022.31},
  url = {https://doi.org/10.20517/cdr.2022.31}
}

RIS

TY  - JOUR
TI  - Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer
AU  - Amy H. Tang
AU  - Richard A. Hoefer
AU  - Mary L. Guye
AU  - Harry D. Bear
PY  - 2022
JO  - Cancer Drug Resistance
DO  - 10.20517/cdr.2022.31
UR  - https://doi.org/10.20517/cdr.2022.31
ER  - 

APA

Tang, A. H., Hoefer, R. A., Guye, M. L., & Bear, H. D. (2022). Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2022.31

Source records